 LEXINGTON, Mass., March 10, 2021 PRNewswire -- Curis, Inc. NASDAQ: CRIS, a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that an abstract for CA-4948, a small molecule IRAK4 inhibitor, has been accepted for poster presentation at the American Association for Cancer Research AACR Annual Meeting, which will be held virtually from April 10-15, 2021. 